EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?

Jeremy W Tomlinson

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci191822 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Jeremy W Tomlinson. Hauptthemen laut MEDLINE: Bardet-Biedl Syndrome, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bardet-Biedl SyndromeObesityGlucagon-Like Peptide-1 Receptor AgonistsAnimalsHumansMiceDiabetes Mellitus, Type 2Disease Models, AnimalGlucagon-Like Peptide-1 ReceptorMice, Knockout

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Zitieren

APA

Tomlinson, J. W. (2025). Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?. Journal of Clinical Investigation. https://doi.org/10.1172/jci191822

Vancouver

Tomlinson JW. Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?. Journal of Clinical Investigation. 2025. doi:10.1172/jci191822

BibTeX
@article{Tomlinson2025,
  author = {Tomlinson, Jeremy W},
  title = {Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci191822}
}
Kostenlos starten →